

# Qian Jiang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1019925/publications.pdf>

Version: 2024-02-01

136  
papers

2,060  
citations

304368

22  
h-index

344852

36  
g-index

161  
all docs

161  
docs citations

161  
times ranked

2535  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 449-459.	1.2	3
2	Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 152-161.	0.6	4
3	Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?. <i>Leukemia</i> , 2022, 36, 482-491.	3.3	17
4	Health-related quality of life in children with chronic myeloid leukemia in the chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 341-350.	1.2	3
5	Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B-related cirrhosis: Multicentre real-world observational study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 306-316.	1.0	4
6	A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. <i>Leukemia</i> , 2022, 36, 1336-1342.	3.3	11
7	Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-12.	0.6	0
8	Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype. <i>International Journal of Laboratory Hematology</i> , 2022, , .	0.7	4
9	Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. <i>Hematological Oncology</i> , 2022, 40, 724-733.	0.8	2
10	Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase. <i>Leukemia</i> , 2022, 36, 1818-1824.	3.3	6
11	Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy. <i>Leukemia</i> , 2022, 36, 2042-2049.	3.3	4
12	The loss or absence of minimal residual disease of <math>\leq 1\%</math> at any time after two cycles of consolidation chemotherapy in CBF&lt;math>\alpha</math>-MYH11-positive acute myeloid leukaemia indicates poor prognosis. <i>British Journal of Haematology</i> , 2021, 192, 265-271.	1.2	13
13	Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. <i>Platelets</i> , 2021, 32, 633-641.	1.1	6
14	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. <i>Leukemia</i> , 2021, 35, 1197-1202.	3.3	9
15	Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 640-648.	0.6	8
16	High PRDM16 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese center. <i>Leukemia and Lymphoma</i> , 2021, 62, 185-193.	0.6	3
17	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. <i>Annals of Hematology</i> , 2021, 100, 1203-1212.	0.8	10
18	The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. <i>Frontiers in Oncology</i> , 2021, 11, 632532.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. <i>American Journal of Hematology</i> , 2021, 96, 561-570.	2.0	5
20	Economics influences therapy decisions in chronic myeloid leukaemia: should it?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3693-3698.	1.2	1
21	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 67.	2.8	9
22	Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult. <i>Journal of Clinical Pathology</i> , 2021, 74, jclinpath-2021-207492.	1.0	2
23	Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2021, 62, 2703-2715.	0.6	3
24	Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services. <i>Frontiers in Psychiatry</i> , 2021, 12, 679932.	1.3	4
25	Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2215-2228.	0.8	3
26	Interferon- $\gamma$ as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2949-2956.	0.6	14
27	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. <i>Frontiers in Oncology</i> , 2021, 11, 706935.	1.3	3
28	PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. <i>British Journal of Haematology</i> , 2021, 195, 722-730.	1.2	3
29	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood</i> , 2021, , .	0.6	10
30	A Predictive Score for Failure-Free Survival in Persons with Chronic Myeloid Leukemia Receiving Imatinib. <i>Blood</i> , 2021, 138, 632-632.	0.6	0
31	COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. <i>Blood</i> , 2021, 138, 634-634.	0.6	5
32	A Predictive Score for Outcomes of Tyrosine Kinase-Inhibitor Therapy in Persons with Chronic Myeloid Leukaemia Presenting in Accelerated Phase. <i>Blood</i> , 2021, 138, 636-636.	0.6	0
33	Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET) <a href="#">Tj ETQq1 1 0 784314 rBT /Over</a>	0.7	14
34	Do persons with chronic myeloid leukaemia have normal or near normal survival?. <i>Leukemia</i> , 2020, 34, 333-335.	3.3	30
35	The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 73-82.	0.8	15
36	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. <i>Blood Advances</i> , 2020, 4, 5846-5857.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. <i>Journal of Hematology and Oncology</i> , 2020, 13, 52.	6.9	13
38	COVID-19 in persons with chronic myeloid leukaemia. <i>Leukemia</i> , 2020, 34, 1799-1804.	3.3	74
39	Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1833-1843.	0.8	3
40	Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. <i>British Journal of Haematology</i> , 2020, 190, 533-544.	1.2	14
41	Mutation topography and risk stratification for <i>de novo</i> acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). <i>British Journal of Haematology</i> , 2020, 190, 274-283.	1.2	18
42	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 67-78.	1.2	11
43	Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e304-e315.	0.2	6
44	Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo. <i>European Journal of Immunology</i> , 2020, 50, 1374-1385.	1.6	22
45	Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. <i>Leukemia</i> , 2020, 34, 2064-2073.	3.3	35
46	COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. <i>Blood</i> , 2020, 136, 46-47.	0.6	17
47	Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. <i>Blood</i> , 2020, 136, 50-51.	0.6	18
48	Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2020, 136, 5-6.	0.6	3
49	Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
50	High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 5459-5467.	1.3	7
51	The prognostic significance of Wilms tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2551-2559.	0.8	8
52	All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1 $\beta$ loop. <i>Haematologica</i> , 2019, 104, 1661-1675.	1.7	25
53	Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2019, 98, 1627-1640.	0.8	14
54	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1733-1742.	0.8	6

#	ARTICLE	IF	CITATIONS
55	<i>S100A16</i> suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 836-851.	1.2	7
56	Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. <i>Leukemia and Lymphoma</i> , 2019, 60, 2181-2189.	0.6	15
57	Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3406-3418.	2.5	8
58	Adverse effects of dasatinib on glucose-lipid metabolism in patients with chronic myeloid leukaemia in the chronic phase. <i>Scientific Reports</i> , 2019, 9, 17601.	1.6	13
59	Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, e1141-e1147.	1.9	14
60	Phlegmonous gastritis in a patient with mixed-phenotype acute leukemia in the neutropenia phase during chemotherapy. <i>Medicine (United States)</i> , 2019, 98, e17777.	0.4	8
61	Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. <i>Medicine (United States)</i> , 2019, 98, e18079.	0.4	7
62	Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety. <i>Frontiers of Medicine</i> , 2019, 13, 344-353.	1.5	5
63	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. <i>Clinical Cancer Research</i> , 2019, 25, 1737-1748.	3.2	26
64	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. <i>Cancer Letters</i> , 2019, 442, 193-201.	3.2	12
65	An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 493-493.	0.6	24
66	The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFβ-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis. <i>Blood</i> , 2019, 134, 2616-2616.	0.6	0
67	Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 735-741.	1.2	16
68	Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL. <i>Annals of Hematology</i> , 2018, 97, 799-811.	0.8	0
69	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. <i>Science China Life Sciences</i> , 2018, 61, 924-933.	2.3	1
70	The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 967-972.	0.6	12
71	The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. <i>Leukemia Research</i> , 2018, 65, 14-19.	0.4	21
72	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 741-750.	2.0	36

#	ARTICLE	IF	CITATIONS
73	Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. <i>BMC Cancer</i> , 2018, 18, 782.	1.1	13
74	A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. <i>Leukemia Research</i> , 2018, 72, 12-19.	0.4	7
75	Prevalence and outcomes of uncommon <i>BCR-ABL1</i> fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. <i>British Journal of Haematology</i> , 2018, 182, 693-700.	1.2	31
76	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). <i>Blood Cancer Journal</i> , 2018, 8, 76.	2.8	21
77	Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study. <i>Blood</i> , 2018, 132, 791-791.	0.6	13
78	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. <i>Medical Science Monitor</i> , 2018, 24, 758-767.	0.5	17
79	Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allografts. Does Pretransplant Conditioning Contribute to Mutation Topography?. <i>Blood</i> , 2018, 132, 2813-2813.	0.6	0
80	Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. <i>Annals of Hematology</i> , 2017, 96, 567-574.	0.8	19
81	Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1013-1022.	1.2	18
82	The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia. <i>Leukemia Research</i> , 2017, 61, 84-88.	0.4	8
83	Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2619-2630.	1.2	26
84	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e487-e496.	2.2	38
85	Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib. <i>Leukemia and Lymphoma</i> , 2017, 58, 1384-1393.	0.6	3
86	Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL. <i>Journal of Translational Medicine</i> , 2017, 15, 184.	1.8	11
87	Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 7028-7028.	0.8	12
88	Cysteine and glycine-rich protein 2 ( <i>CSRP2</i> ) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. <i>Oncotarget</i> , 2017, 8, 35984-36000.	0.8	23
89	CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 105397-105406.	0.8	10
90	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. <i>Oncotarget</i> , 2017, 8, 41620-41630.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). <i>Leukemia Research</i> , 2016, 44, 40-44.	0.4	29
92	Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1549-1555.	1.2	21
93	Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1539-1547.	1.2	45
94	Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. <i>Blood</i> , 2016, 127, 243-250.	0.6	26
95	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. <i>Chinese Journal of Cancer</i> , 2016, 35, 46.	4.9	11
96	Fabrication of mPEGylated graphene oxide/poly(2-dimethyl aminoethyl methacrylate) nanohybrids and their primary application for small interfering RNA delivery. <i>Journal of Applied Polymer Science</i> , 2016, 133, .	1.3	15
97	Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. <i>BMC Cancer</i> , 2016, 16, 269.	1.1	31
98	Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. <i>Medicine (United States)</i> , 2016, 95, e2486.	0.4	14
99	Small activating RNA binds to the genomic target site in a seed-region-dependent manner. <i>Nucleic Acids Research</i> , 2016, 44, 2274-2282.	6.5	43
100	<i>Helicobacter pylori</i> infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. <i>Platelets</i> , 2016, 27, 223-229.	1.1	7
101	Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study. <i>Blood</i> , 2016, 128, 1928-1928.	0.6	6
102	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience. <i>Blood</i> , 2016, 128, 2308-2308.	0.6	1
103	Aberrant TNFAIP3 Induces Mesenchymal Stem Cell Impairment Via the NF-Kb/SMAD7 Signaling Pathway in Immune Thrombocytopenia. <i>Blood</i> , 2016, 128, 364-364.	0.6	1
104	Patients' and Physicians' Concerns about Tyrosine Kinase-Inhibitor Therapy in Chronic Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3092-3092.	0.6	0
105	ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study. <i>Blood</i> , 2016, 128, 2902-2902.	0.6	0
106	Co-Morbidity Profile Influences Work, Daily Life and Health-Related Quality-of-Life in Persons with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy. <i>Blood</i> , 2016, 128, 1927-1927.	0.6	0
107	The Initial Level of MLL-PTD Affects the Prognosis of Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5241-5241.	0.6	0
108	C-KIT- Mutated t(8;21)AML Patients with >3log Reduction of MRD Conferred a Very High Relapse and Need HSCT to Improve Outcome. <i>Blood</i> , 2016, 128, 1620-1620.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study. <i>Blood</i> , 2016, 128, 5439-5439.	0.6	1
110	Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. <i>Leukemia Research</i> , 2015, 39, 1319-1324.	0.4	24
111	ADAM28 overexpression regulated via the PI3K/Akt pathway is associated with relapse in de novo adult B-cell acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2015, 39, 1229-1238.	0.4	15
112	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3116-3123.	0.6	31
113	Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance. <i>Leukemia and Lymphoma</i> , 2015, 56, 2075-2081.	0.6	7
114	Age and Cost Are Associated with Patient Preference for Stopping Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1585-1585.	0.6	4
115	Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS). <i>Blood</i> , 2015, 126, 2152-2152.	0.6	0
116	Varying Responses of PML-Rara with Different Genetic Mutations to Arsenic Trioxide. <i>Blood</i> , 2015, 126, 3678-3678.	0.6	0
117	Small indels induced by CRISPR/Cas9 in the 5' region of microRNA lead to its depletion and Drosha processing retardance. <i>RNA Biology</i> , 2014, 11, 1243-1249.	1.5	31
118	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center. <i>Leukemia Research</i> , 2014, 38, 1435-1440.	0.4	63
119	Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA. <i>Journal of Controlled Release</i> , 2014, 176, 104-114.	4.8	102
120	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1314-1321.	2.0	36
121	Prevalence and Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Comprehensive Large-Scale Study from a Single Chinese Center. <i>Blood</i> , 2014, 124, 1000-1000.	0.6	0
122	Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study. <i>Blood</i> , 2014, 124, 2778-2778.	0.6	0
123	IKZF1 Status As an Independent Prognostic Marker in Adult Common B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1075-1075.	0.6	0
124	PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2013, 54, 1442-1449.	0.6	23
125	Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABLIS or log reduction from the baseline level?. <i>Leukemia Research</i> , 2013, 37, 1035-1040.	0.4	28
126	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , 2013, 121, 4056-4062.	0.6	277



#	ARTICLE	IF	CITATIONS
127	Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1346-1346.	0.6	0
128	Philadelphia-Positive Leukemia Patients With The Y253H Or F359V Mutations Have a High Risk Of Developing New Mutations In The Setting Of Dasatinib Resistance. <i>Blood</i> , 2013, 122, 5188-5188.	0.6	0
129	The differences and correlations of <i>BCR-ABL</i> transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia. <i>American Journal of Hematology</i> , 2012, 87, 1065-1069.	2.0	15
130	CD34 Expression On the Blasts of Bone Marrow Is a Novel Predictor of Poor Prognosis Independent of FLT3-ITD in Acute Myeloid Leukemia with NPM1-Mutation.. <i>Blood</i> , 2012, 120, 2491-2491.	0.6	0
131	Risk-Stratification Treatment Directed by Minimal Residual Disease Improves the Outcome of Acute Myeloid Leukemia with t(8;21) in First Complete Remission: Results of the AML05 Multicentre Trial. <i>Blood</i> , 2012, 120, 139-139.	0.6	1
132	Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. <i>Blood</i> , 2011, 117, 3032-3040.	0.6	80
133	Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. <i>Blood</i> , 2011, 118, 4161-4161.	0.6	0
134	Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up. <i>Blood</i> , 2010, 116, 2347-2347.	0.6	0
135	Subclinical Alterations in Coagulation in Patients during Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 5292-5292.	0.6	0
136	Immunophenotypic characteristics of <i>ZNF384</i> rearrangement compared with <i>BCR-ABL1</i> , <i>KMT2A</i> rearrangement, and other adult <i>B-cell</i> precursor acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 0, , .	0.7	4